Image around Wikipedia
Earlier this month, a curative association Pfizer announced that it might ask a Food and Drug Administration to concede it to marketplace a cholesterol-lowering statin Lipitor over a opposite after a obvious expires in November.
The FDA has not nonetheless signaled either it would approve Pfizer’s proposal. And some doctors have reacted coolly to a probability of an OTC chronicle of Lipitor.
But a growth offers regulators